speb/financial-data huggingface dataset:
CVS.TO income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: 8344000000.00
CVS.TO income_statement (annual, 2023-12-31) — EBIT: 13831000000.00
CVS.TO income_statement (annual, 2023-12-31) — EBITDA: 18197000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Employee Benefits: 3250000000.00
CVS.TO cash_flow (annual, 2023-12-31) — End Cash Position: 8525000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Financing Cash Flow: 2683000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Free Cash Flow: 10395000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of Business: 0.00
CVS.TO income_statement (annual, 2023-12-31) — Gain On Sale Of Business: 0.00
CVS.TO income_statement (annual, 2023-12-31) — Gain On Sale Of Ppe: -349000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -297000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Goodwill: 91272000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 120506000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Gross PPE: 51134000000.00
CVS.TO income_statement (annual, 2023-12-31) — Gross Profit: 54431000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Held To Maturity Securities: 1183000000.00
CVS.TO income_statement (annual, 2023-12-31) — Impairment Of Capital Assets: 0.00
CVS.TO income_statement (annual, 2023-12-31) — Interest Expense: 2658000000.00
CVS.TO income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 2658000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Inventories Adjustments Allowances: -607000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Inventory: 18025000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Invested Capital: 138071000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Investing Cash Flow: -20889000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 19765000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Investments And Advances: 23019000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Issuance Of Debt: 16098000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Land And Improvements: 1958000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Leases: 6511000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 16034000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Long Term Debt: 58638000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 74672000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 10898000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -3166000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 20842000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Minority Interest: 175000000.00
CVS.TO income_statement (annual, 2023-12-31) — Minority Interests: -24000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: -16612000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: -2012000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Net Debt: 53414000000.00
CVS.TO income_statement (annual, 2023-12-31) — Net Income: 8344000000.00
CVS.TO income_statement (annual, 2023-12-31) — Net Income Common Stockholders: 8344000000.00
CVS.TO income_statement (annual, 2023-12-31) — Net Income Continuous Operations: 8368000000.00
CVS.TO income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: 8344000000.00
CVS.TO income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: 8344000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: 8368000000.00
CVS.TO income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: 8368000000.00
CVS.TO income_statement (annual, 2023-12-31) — Net Interest Income: -2658000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: -1314000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: 7932000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: 7732000000.00
CVS.TO income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -2658000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Net Other Financing Charges: -382000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Net Other Investing Changes: 68000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Net PPE: 30435000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -3031000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Net Short Term Debt Issuance: 200000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Net Tangible Assets: -44045000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 4311000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 4311000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 3250000000.00
CVS.TO income_statement (annual, 2023-12-31) — Normalized EBITDA: 19053000000.00
CVS.TO income_statement (annual, 2023-12-31) — Normalized Income: 8985144000.00
CVS.TO cash_flow (annual, 2023-12-31) — Operating Cash Flow: 13426000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Operating Gains Losses: 349000000.00
CVS.TO income_statement (annual, 2023-12-31) — Operating Income: 14599000000.00
CVS.TO income_statement (annual, 2023-12-31) — Operating Revenue: 357776000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 1288000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Current Assets: 3151000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Current Borrowings: 2772000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 1141000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -297000000.00
CVS.TO income_statement (annual, 2023-12-31) — Other Income Expense: -768000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 29234000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Inventories: 18632000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Investments: 3254000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Other Non Cash Items: 264000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 4660000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 11670000000.00
CVS.TO income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 88000000.00
CVS.TO income_statement (annual, 2023-12-31) — Other Operating Expenses: 39832000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Payable: 34923000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Properties: 17252000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Receivables: 19605000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 3259000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Payables: 49820000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 73335000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
CVS.TO income_statement (annual, 2023-12-31) — Pretax Income: 11173000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 277000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Properties: 0.00
CVS.TO cash_flow (annual, 2023-12-31) — Purchase Of Business: -16612000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Purchase Of Investment: -9043000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Purchase Of PPE: -3031000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Receivables: 35227000000.00
CVS.TO income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 303345000000.00
CVS.TO income_statement (annual, 2023-12-31) — Reconciled Depreciation: 4366000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Repayment Of Debt: -8166000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -2012000000.00
CVS.TO income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: 507000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Retained Earnings: 61604000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Sale Of Business: 0.00
CVS.TO cash_flow (annual, 2023-12-31) — Sale Of Investment: 7729000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Share Issued: 1768000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Short Term Debt Issuance: 5200000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Short Term Debt Payments: -5000000000.00
CVS.TO income_statement (annual, 2023-12-31) — Special Income Charges: -856000000.00
CVS.TO cash_flow (annual, 2023-12-31) — Stock Based Compensation: 588000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Stockholders Equity: 76461000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Tangible Book Value: -44045000000.00
CVS.TO income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -214856000.00
CVS.TO income_statement (annual, 2023-12-31) — Tax Provision: 2805000000.00
CVS.TO income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.25
CVS.TO balance_sheet (annual, 2023-12-31) — Total Assets: 249728000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Total Capitalization: 135099000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Total Debt: 79385000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 76636000000.00
CVS.TO income_statement (annual, 2023-12-31) — Total Expenses: 343177000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 173092000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 181870000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 93903000000.00
CVS.TO income_statement (annual, 2023-12-31) — Total Operating Income As Reported: 13743000000.00
CVS.TO income_statement (annual, 2023-12-31) — Total Unusual Items: -856000000.00
CVS.TO income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -856000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 480000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Treasury Stock: 33838000000.00
CVS.TO balance_sheet (annual, 2023-12-31) — Working Capital: -11331000000.00
CVS.TO income_statement (quarterly, 2024-09-30) — Gain On Sale Of Ppe: 0.00
CVS.TO cash_flow (quarterly, 2024-09-30) — Issuance Of Debt: 600000000.00
CVS.TO cash_flow (quarterly, 2024-09-30) — Long Term Debt Issuance: 0.00
CVS.TO income_statement (quarterly, 2024-09-30) — Restructuring And Mergern Acquisition: 1169000000.00
CVS.TO cash_flow (quarterly, 2024-09-30) — Short Term Debt Issuance: 600000000.00
CVS.TO cash_flow (quarterly, 2024-09-30) — Short Term Debt Payments: 200000000.00
CVS.TO income_statement (quarterly, 2024-09-30) — Special Income Charges: -1169000000.00
CVS.TO income_statement (quarterly, 2024-09-30) — Total Unusual Items: -1169000000.00
CVS.TO income_statement (quarterly, 2024-09-30) — Total Unusual Items Excluding Goodwill: -1169000000.00
CVS.TO income_statement (annual, 2024-12-31) — +Operating Expense: 41706000000.00
CVS.TO income_statement (annual, 2024-12-31) — +Total Revenue: 372809000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Accounts Payable: 15892000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Accounts Receivable: 14612000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -23447000000.00
CVS.TO balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -23447000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 840000000.00
CVS.TO cash_flow (quarterly, 2024-12-31) — Asset Impairment Charge: 0.00
CVS.TO balance_sheet (annual, 2024-12-31) — Available For Sale Securities: 23777000000.00
CVS.TO income_statement (annual, 2024-12-31) — Basic Average Shares: 6914878396.00
CVS.TO income_statement (quarterly, 2024-12-31) — Basic Average Shares: 6914878396.00
CVS.TO income_statement (annual, 2024-12-31) — Basic EPS: 0.67
CVS.TO income_statement (quarterly, 2024-12-31) — Basic EPS: 0.24
CVS.TO cash_flow (annual, 2024-12-31) — Beginning Cash Position: 8525000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 4632000000.00
CVS.TO balance_sheet (quarterly, 2024-12-31) — Buildings And Improvements: 4632000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Capital Expenditure: -2781000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 16650000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Capital Stock: 49661000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 8586000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 10993000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -3373000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -1135000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -7613000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 9107000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Change In Account Payable: 2335000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Change In Inventory: -102000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Change In Other Current Assets: -38000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: -3542000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Change In Payable: 5092000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 5092000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Change In Receivables: -1301000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Change In Working Capital: 109000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Changes In Account Receivables: -1301000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Changes In Cash: 359000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Commercial Paper: 2119000000.00
CVS.TO balance_sheet (quarterly, 2024-12-31) — Commercial Paper: 2119000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Common Stock: 49661000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Common Stock Dividend Paid: -3373000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Common Stock Equity: 75560000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Common Stock Payments: -3023000000.00
CVS.TO cash_flow (quarterly, 2024-12-31) — Common Stock Payments: 0.00
CVS.TO income_statement (annual, 2024-12-31) — Cost Of Revenue: 321408000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 20810000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Current Assets: 68645000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 1751000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Current Debt: 5743000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 7494000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Current Liabilities: 84609000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Deferred Income Tax: -572000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Deferred Tax: -572000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Defined Pension Benefit: 3311000000.00
CVS.TO balance_sheet (quarterly, 2024-12-31) — Defined Pension Benefit: 3311000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 4597000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 4597000000.00
CVS.TO income_statement (annual, 2024-12-31) — Diluted Average Shares: 6931355469.00
CVS.TO income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 6925863112.00
CVS.TO income_statement (annual, 2024-12-31) — Diluted EPS: 0.67
CVS.TO income_statement (quarterly, 2024-12-31) — Diluted EPS: 0.24
CVS.TO income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: 4614000000.00
CVS.TO income_statement (annual, 2024-12-31) — EBIT: 9106000000.00
CVS.TO income_statement (annual, 2024-12-31) — EBITDA: 13703000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Employee Benefits: 3311000000.00
CVS.TO balance_sheet (quarterly, 2024-12-31) — Employee Benefits: 3311000000.00
CVS.TO cash_flow (annual, 2024-12-31) — End Cash Position: 8884000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Financing Cash Flow: -1135000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Free Cash Flow: 6326000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of Business: 0.00
CVS.TO income_statement (annual, 2024-12-31) — Gain On Sale Of Business: 0.00
CVS.TO income_statement (annual, 2024-12-31) — Gain On Sale Of Ppe: 0.00
CVS.TO income_statement (quarterly, 2024-12-31) — Gain On Sale Of Ppe: 0.00
CVS.TO balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -120000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Goodwill: 91272000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 118595000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Gross PPE: 52384000000.00
CVS.TO income_statement (annual, 2024-12-31) — Gross Profit: 51401000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Held To Maturity Securities: 1354000000.00
CVS.TO income_statement (annual, 2024-12-31) — Impairment Of Capital Assets: 0.00
CVS.TO income_statement (annual, 2024-12-31) — Interest Expense: 2958000000.00
CVS.TO income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 2958000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Inventory: 18107000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Invested Capital: 141830000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Investing Cash Flow: -7613000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 25131000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Investments And Advances: 28934000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Issuance Of Debt: 9832000000.00
CVS.TO cash_flow (quarterly, 2024-12-31) — Issuance Of Debt: 4273000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Land And Improvements: 1847000000.00
CVS.TO balance_sheet (quarterly, 2024-12-31) — Land And Improvements: 1847000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Leases: 6725000000.00
CVS.TO balance_sheet (quarterly, 2024-12-31) — Leases: 6725000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 14899000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Long Term Debt: 60527000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 75426000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 7913000000.00
CVS.TO cash_flow (quarterly, 2024-12-31) — Long Term Debt Issuance: 2954000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -4773000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 23236000000.00
CVS.TO balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 23236000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Minority Interest: 170000000.00
CVS.TO income_statement (annual, 2024-12-31) — Minority Interests: 28000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: -95000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -3023000000.00
CVS.TO cash_flow (quarterly, 2024-12-31) — Net Common Stock Issuance: 0.00
CVS.TO balance_sheet (annual, 2024-12-31) — Net Debt: 57684000000.00
CVS.TO income_statement (annual, 2024-12-31) — Net Income: 4614000000.00
CVS.TO income_statement (annual, 2024-12-31) — Net Income Common Stockholders: 4614000000.00
CVS.TO income_statement (annual, 2024-12-31) — Net Income Continuous Operations: 4586000000.00
CVS.TO income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 4614000000.00
CVS.TO income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 4614000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: 4586000000.00
CVS.TO income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: 4586000000.00
CVS.TO income_statement (annual, 2024-12-31) — Net Interest Income: -2958000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: -4838000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: 5059000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: 3140000000.00
CVS.TO income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -2958000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -159000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Net Other Investing Changes: 101000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Net PPE: 28937000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -2781000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Net Short Term Debt Issuance: 1919000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Net Tangible Assets: -43035000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 3806000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 3806000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 3311000000.00
CVS.TO balance_sheet (quarterly, 2024-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 3311000000.00
CVS.TO income_statement (annual, 2024-12-31) — Normalized EBITDA: 14391000000.00
CVS.TO income_statement (annual, 2024-12-31) — Normalized Income: 5127248000.00
CVS.TO cash_flow (annual, 2024-12-31) — Operating Cash Flow: 9107000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Operating Gains Losses: -491000000.00
CVS.TO income_statement (annual, 2024-12-31) — Operating Income: 9695000000.00
CVS.TO income_statement (annual, 2024-12-31) — Operating Revenue: 372809000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 1260000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Current Assets: 3076000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Current Borrowings: 3624000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 1183000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -120000000.00
CVS.TO income_statement (annual, 2024-12-31) — Other Income Expense: -589000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 27323000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Investments: 3803000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Other Non Cash Items: -502000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 4793000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 10333000000.00
CVS.TO income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 99000000.00
CVS.TO income_statement (annual, 2024-12-31) — Other Operating Expenses: 41706000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Payable: 39230000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Properties: 15944000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Receivables: 21857000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 2407000000.00
CVS.TO income_statement (annual, 2024-12-31) — Other Special Charges: -491000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Payables: 55122000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 75932000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Preferred Stock: 0.00
CVS.TO income_statement (annual, 2024-12-31) — Pretax Income: 6148000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 361000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Properties: 0.00
CVS.TO balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
CVS.TO cash_flow (annual, 2024-12-31) — Purchase Of Business: -95000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Purchase Of Investment: -15191000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Purchase Of PPE: -2781000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Receivables: 36469000000.00
CVS.TO income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 321408000000.00
CVS.TO income_statement (annual, 2024-12-31) — Reconciled Depreciation: 4597000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Repayment Of Debt: -4773000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -3023000000.00
CVS.TO cash_flow (quarterly, 2024-12-31) — Repurchase Of Capital Stock: 0.00
CVS.TO income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 1179000000.00
CVS.TO income_statement (quarterly, 2024-12-31) — Restructuring And Mergern Acquisition: 10000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Retained Earnings: 62837000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Sale Of Business: 0.00
CVS.TO cash_flow (annual, 2024-12-31) — Sale Of Investment: 10353000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Share Issued: 1778000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Short Term Debt Issuance: 1919000000.00
CVS.TO cash_flow (quarterly, 2024-12-31) — Short Term Debt Issuance: 1319000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Short Term Debt Payments: 0.00
CVS.TO cash_flow (quarterly, 2024-12-31) — Short Term Debt Payments: 0.00
CVS.TO income_statement (annual, 2024-12-31) — Special Income Charges: -688000000.00
CVS.TO income_statement (quarterly, 2024-12-31) — Special Income Charges: 381000000.00
CVS.TO cash_flow (annual, 2024-12-31) — Stock Based Compensation: 540000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Stockholders Equity: 75560000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Tangible Book Value: -43035000000.00
CVS.TO income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -174752000.00
CVS.TO income_statement (annual, 2024-12-31) — Tax Provision: 1562000000.00
CVS.TO income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.25
CVS.TO balance_sheet (annual, 2024-12-31) — Total Assets: 253215000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Total Capitalization: 136087000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Total Debt: 82920000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 75730000000.00
CVS.TO income_statement (annual, 2024-12-31) — Total Expenses: 363114000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 177485000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 184570000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 92876000000.00
CVS.TO income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 8516000000.00
CVS.TO income_statement (annual, 2024-12-31) — Total Unusual Items: -688000000.00
CVS.TO income_statement (quarterly, 2024-12-31) — Total Unusual Items: 381000000.00
CVS.TO income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -688000000.00
CVS.TO income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 381000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 518000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Treasury Stock: 36818000000.00
CVS.TO balance_sheet (annual, 2024-12-31) — Working Capital: -15964000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — +Operating Expense: 11022000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — +Total Revenue: 94588000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 16534000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 16660000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 23618000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Basic Average Shares: 6925863112.00
CVS.TO income_statement (quarterly, 2025-03-31) — Basic EPS: 0.26
CVS.TO cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 8884000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -743000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 16503000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Capital Stock: 49837000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 10076000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 12654000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -840000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -2332000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -762000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 4556000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 2619000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Change In Inventory: 722000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: -1101000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: 1876000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Change In Payable: 2983000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 2983000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Change In Receivables: -3053000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 1427000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: -3053000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Changes In Cash: 1462000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Commercial Paper: 1259000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Common Stock: 49837000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Common Stock Dividend Paid: -840000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 76929000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Common Stock Payments: 0.00
CVS.TO income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 80192000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 22369000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Current Assets: 73191000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 1909000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Current Debt: 5670000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 7579000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 88961000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: -169000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Deferred Tax: -169000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Defined Pension Benefit: 1924000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 1154000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 1154000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 6942340185.00
CVS.TO income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.26
CVS.TO income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 1779000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — EBIT: 3402000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — EBITDA: 4556000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Employee Benefits: 1924000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — End Cash Position: 10346000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -2332000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 3813000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Gain Loss On Sale Of Business: 236000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 59000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Goodwill: 91203000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 117773000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Gross PPE: 28560000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Gross Profit: 14396000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Held To Maturity Securities: 1346000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Interest Expense: 785000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 785000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Inventory: 17385000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Invested Capital: 141639000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -762000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 24964000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 28906000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 14594000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 59040000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 73634000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -743000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Minority Interest: 181000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Minority Interests: -3000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: -20000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 0.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Net Debt: 54634000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Net Income: 1779000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 1779000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 1782000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1779000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1779000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 1782000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 1782000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Net Interest Income: -785000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: -18000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -1602000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -743000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -785000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -34000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Net Other Investing Changes: 19000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Net PPE: 28560000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -743000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Net Short Term Debt Issuance: -859000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: -40844000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 3664000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 3664000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 1924000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 4556000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Normalized Income: 1779000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 4556000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 236000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Operating Income: 3374000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Operating Revenue: 94588000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 1262000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 3527000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Current Borrowings: 4411000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 1570000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: 59000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Other Income Expense: 28000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 26570000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Investments: 3942000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 5231000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 10292000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 28000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 11022000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Payable: 40909000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Properties: 28560000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Receivables: 22965000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 2578000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Payables: 57443000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 79812000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
CVS.TO income_statement (quarterly, 2025-03-31) — Pretax Income: 2617000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 144000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Purchase Of Business: -20000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -3552000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -743000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Receivables: 39625000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 80192000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 1154000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -743000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: 0.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 63768000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 3534000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Share Issued: 1779000000.00
CVS.TO cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 126000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 76929000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: -40844000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
CVS.TO income_statement (quarterly, 2025-03-31) — Tax Provision: 835000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.32
CVS.TO balance_sheet (quarterly, 2025-03-31) — Total Assets: 255585000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 135969000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Total Debt: 81213000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 77110000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Total Expenses: 91214000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 178475000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 182394000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 89514000000.00
CVS.TO income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 3374000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 517000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 36735000000.00
CVS.TO balance_sheet (quarterly, 2025-03-31) — Working Capital: -15770000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — +Operating Expense: 11212000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — +Total Revenue: 98915000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 17258000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 16350000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Available For Sale Securities: 24303000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Basic Average Shares: 6953324900.00
CVS.TO income_statement (quarterly, 2025-06-30) — Basic EPS: 0.15
CVS.TO cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 10346000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -607000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 16234000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Capital Stock: 50020000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 11787000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 14173000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Cash Dividends Paid: -866000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 806000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -1024000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 1897000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Change In Account Payable: 1212000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Change In Inventory: -51000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Change In Other Current Assets: 132000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -118000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Change In Payable: 814000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 814000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Change In Receivables: -1086000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -309000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -1086000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Changes In Cash: 1679000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Commercial Paper: 3040000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Common Stock: 50020000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Common Stock Dividend Paid: -866000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 77379000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Common Stock Payments: 0.00
CVS.TO income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 85322000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 23101000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Current Assets: 75649000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 1906000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Current Debt: 9200000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 11106000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 94162000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: -114000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Deferred Tax: -114000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Defined Pension Benefit: 1858000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 1171000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 1171000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 6975294331.00
CVS.TO income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.15
CVS.TO income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 1021000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — EBIT: 2410000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — EBITDA: 3581000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Employee Benefits: 1858000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — End Cash Position: 12025000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 806000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 1290000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Gain Loss On Sale Of Business: 0.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 272000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Goodwill: 91203000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 117427000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Gross PPE: 28337000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Gross Profit: 13593000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Held To Maturity Securities: 1376000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Interest Expense: 763000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 763000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Inventory: 17447000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Invested Capital: 143869000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -1024000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Investmentin Financial Assets: 25679000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 29858000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 14328000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 57290000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 71618000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -19000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Minority Interest: 172000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Minority Interests: 8000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: -119000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 0.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Net Debt: 54703000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Net Income: 1021000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 1021000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 1013000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 1021000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 1021000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 1013000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 1013000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Net Interest Income: -763000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: -302000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: 1761000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -19000000.00
CVS.TO income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -763000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -136000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Net Other Investing Changes: 4000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Net PPE: 28337000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -607000000.00
CVS.TO cash_flow (quarterly, 2025-06-30) — Net Short Term Debt Issuance: 1780000000.00
CVS.TO balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -40048000000.00